Latest Breaking News On - ஐரோப்பிய ஹீமாட்டாலஜி சங்கம் - Page 6 : comparemela.com

(0) - Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive form of Non-Hodgkin s Lymphoma (NHL), representing 30-40% of cases. Nearly half of DLBCL patients are not cured by first-line treatment, leaving a large number of patients at risk of worsening disease 1 - Naratuximab emtansine, the most advanced CD37 targeting antibody drug conjugate (ADC) in clinical development for DLBCL, showed promising safety and efficacy results in combination with rituximab for the treatment of R/R DLBCL and other B-cell malignancies - Phase II data presented by Dr. Moshe Yair Levy at the 2021 European Hematology Association (EHA) conference as a late breaking abstract (LB1903) demonstrated that the naratuximab emtansine/rituximab combination could represent a new treatment approach, particularly for heavily pre-treated

Bertrand ducreyPrnewswire debiopharmBaylor university medical centerEuropean hematology associationMoshe yair levyHematology associationResponse rateOrphan drugMantle cell lymphomaFollicular lymphomaAcute myeloidSwiss biotech success storyபேலர் பல்கலைக்கழகம் மருத்துவ மையம்ஐரோப்பிய ஹீமாட்டாலஜி சங்கம்மோஷ் யேர் வசூல் செய்தல்ஹீமாட்டாலஜி சங்கம்